This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Ways To Manage Unexpected Costs shares smart strategies to track expenses, reduce leakage, and prepare an emergency fund for surprises.
21,677 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Oracle has fallen this year as investors weigh legacy strengths against AI disruption. This guide breaks down the AI ...
Harvey, an AI-driven legal tech startup, has surged to an $11 billion valuation after attracting OpenAI backing. The ...
As Warren Buffett's successor, Greg Abel has begun steering Berkshire Hathaway's portfolio with careful turns. A nota...
Summer markets often hinge on headlines. This guide explains how geopolitical tensions could impact portfolios and of...
Trump’s move to bring Elon Musk into a China diplomacy frame marks a dramatic shift for investors. The pairing could ...
When a seasoned manager shifts more weight toward mid-cap stocks, the move often signals conviction about the sector'...
California’s CEQA exemption is speeding residential projects, yet fault lines surface as opponents deploy new delay t...
Pi Network says it has solved crypto’s biggest problem by tying token use to verified user engagement and sustained u...
Markets have been rallying, but a flashing warning sign could signal trouble ahead. This guide explains what to watch...
A 64-year-old selling a family business in California could see a substantial tax bill after a $3.2 million sale, und...
When an institutional investor takes a large position in a biotech stock, it can signal potential credibility or risk...